Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neuland LaboratoriesNSE:NEULANDLAB -2.27%93 EV-to-EBIT is 46.22 as of Jul. 23, 2026, which is 121% above its 10-year median of 20.95. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 93/100 and a GF Value™ of ₹16,136.34 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 691 Drug Manufacturers companies, Neuland Laboratories ranks worse than 84.66% on this metric.
The historical rank and industry rank for Neuland Laboratories's EV-to-EBIT or its related term are showing as below:
NSE:NEULANDLAB'
s EV-to-EBIT Range Over the Past 10 Years
Min: 5.84 Med: 20.95 Max: 226.7
Current: 46.22
During the past 13 years, the highest EV-to-EBIT of Neuland Laboratories was 226.70. The lowest was 5.84. And the median was 20.95.
NSE:NEULANDLAB's EV-to-EBIT is ranked worse than 84.66% of 691
companies
in the Drug Manufacturers industry
Industry Median: 15.7
vs NSE:NEULANDLAB: 46.22
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Neuland Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was ₹154,052 Mil.
Neuland Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,129 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuland Laboratories EV-to-EBIT Related Terms
Neuland Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NEULANDLAB vs ZTS, UTHR: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's EV-to-EBIT falls into.
Neuland Laboratories's current Enterprise Value is ₹237,072 Mil.
Neuland Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,129 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuland Laboratories (NSE:NEULANDLAB) has a EV-to-EBIT of 46.22 as of Jul. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Neuland Laboratories and its competitors. This is 121% above median its historical median of 20.95. Over the past decade, Neuland Laboratories' EV-to-EBIT has ranged from 5.84 to 226.70. According to the industry distribution chart, Neuland Laboratories ranks #585 out of 691 companies in the Drug Manufacturers industry, placing it in the top 84.7%.
Is Neuland Laboratories' EV-to-EBIT too high?
Neuland Laboratories' current EV-to-EBIT of 46.22 is 121% above median its 10-year median of 20.95. Over the past 10 years, this metric has ranged from a low of 5.84 to a high of 226.70. The Drug Manufacturers industry median EV-to-EBIT is 15.70. Neuland Laboratories' value of 46.22 is 194.4% above this industry median. Based on the distribution chart, Neuland Laboratories ranks #585 out of 691 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neuland Laboratories has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #585 out of 691 companies for EV-to-EBIT. This places Neuland Laboratories in the lower half of its industry. The industry median EV-to-EBIT is 15.70. Neuland Laboratories' value of 46.22 is 194.4% above this benchmark. Historically, Neuland Laboratories' own EV-to-EBIT has ranged from 5.84 to 226.70 over the past decade. While the company's 10-year median is 20.95 vs. the industry median of 15.70, Neuland Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.70, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current EV-to-EBIT of 46.22 is 194.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current EV-to-EBIT is 46.22, which is 121% above median its own 10-year median of 20.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,136.34, compared to a current price of ₹18,466.00 — trading 14.4% above its estimated fair value. The current EV-to-EBIT is 46.22, which is 121% above median its 10-year median of 20.95 and 194.4% above the Drug Manufacturers industry median of 15.70. Neuland Laboratories' overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current EV-to-EBIT is 46.22 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹18,466.00 is trading 14.4% above its estimated GF Value™ of ₹16,136.34.
GuruFocus considers Neuland Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:NEULANDLAB:
EV-to-EBIT: 46.22 (121% above median its 10-year median of 20.95)
GF Value™: ₹16,136.34 vs. price of ₹18,466.00 (14.4% above fair value)
Industry Position: 194.4% above the Drug Manufacturers median (#585 of 691)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
93GF Score
Get the complete analysis for NSE:NEULANDLAB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
